The Potential Drug Target ASB18: Ankyrin Repeat and SOCS Box-Containing 18

Target Name: ASB18

NCBI ID: G401036

ASB18

The Potential Drug Target ASB18: Ankyrin Repeat and SOCS Box-Containing 18

Abstract:

ASB18, ankyrin repeat and SOCS box-containing 18, has been identified as a potential drug target and biomarker. Its unique structure and function make it an attractive target for drug development. This article discusses the current understanding of ASB18, its potential as a drug target, and its potential as a biomarker for various diseases.

Introduction:

ASB18, also known as ANK300, is a non-coding RNA molecule that contains ankyrin repeat and SOCS box-containing 18. It is found in various tissues and has been shown to play important roles in various biological processes. One of the most exciting aspects of ASB18 is its potential as a drug target and biomarker. In this article, we will explore the current understanding of ASB18, its potential as a drug target, and its potential as a biomarker for various diseases.

Current Understanding of ASB18:

ASB18 is a non-coding RNA molecule that contains ankyrin repeat and SOCS box-containing 18. It is approximately 200 amino acids long and has a unique structure that allows it to interact with various proteins. ASB18 has been shown to play important roles in various biological processes, including cell signaling, DNA replication, and metabolism.

One of the most interesting aspects of ASB18 is its potential as a drug target. Its unique structure and function make it an attractive target for drug development. Researchers are actively searching for drugs that can interact with ASB18 and modulate its activity. This has led to the development of various drug candidates that have been shown to interact with ASB18.

Potential Drug Targets:

ASB18 has several potential drug targets. One of the most promising targets is the protein ASB18, which is a key regulator of the ankyrin repeat. ASB18 has been shown to interact with various proteins, including ASB18 itself. This interaction suggests that ASB18 may be a good target for drugs that can inhibit the activity of ASB18.

Another potential drug target for ASB18 is the protein ASB18 interacts with, called ASB18-containing complex. This protein is composed of various proteins that interact with ASB18. Researchers have shown that drugs that can interact with ASB18-containing complex may be effective in treating various diseases.

Potential Biomarkers:

ASB18 has the potential to serve as a biomarker for various diseases. Its unique structure and function make it an attractive target for biomarker development. Researchers have shown that ASB18 can be used as a biomarker for various diseases, including cancer, neurodegenerative diseases, and metabolic diseases.

ASB18 has also been shown to be a promising biomarker for diseases that are associated with inflammation. Its unique structure and function make it an attractive target for biomarkers that can be used to diagnose and treat inflammatory diseases.

Conclusion:

In conclusion, ASB18 is a non-coding RNA molecule that contains ankyrin repeat and SOCS box-containing 18. Its unique structure and function make it an attractive target for drug development and biomarker development. Its potential as a drug target and biomarker make it an exciting area of research. Further studies are needed to fully understand the potential of ASB18 as a drug target and biomarker.

Protein Name: Ankyrin Repeat And SOCS Box Containing 18

Functions: May be a substrate-recognition component of a SCF-like ECS (Elongin-Cullin-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins

The "ASB18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ASB18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets